apremilast vs Roflumilast (Zoryve)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
apremilast · Otezla
Marketed by Amgen
NCT01194219 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 844 participants, with 562 assigned to apremilast and 282 to placebo. The primary clinical endpoint was met: PASI-75 response at Week 16 was 33.1% with apremilast versus 5.3% with placebo (p<0.0001).
Next expected readout: January 2027 · NCT07908641 (registry estimate)
Reported efficacy
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Apremilast 33.1% vs Placebo 11.5% (met)
Result source: NCT03701763
Roflumilast (Zoryve)
Marketed by Arcutis Biotherapeutics and partners
NCT06648772 · Phase 3 · completed
The study randomly assigned 190 participants to roflumilast cream or vehicle cream and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a clinical psoriasis severity measure, but whether that endpoint was met cannot be determined because results are not available.
Next expected readout: July 2027 · NCT07725822 (registry estimate)
Reported efficacy
Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%) (met)
Result source: NCT04211389
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | apremilast | Roflumilast (Zoryve) |
|---|---|---|
| PASI 75 | 33.1% vs 5.3%+27.8 vs placeboNCT0119421910 other results
| 41.6% vs 7.6%+34 vs placeboNCT042113639 other results
|
| PASI 90 | 55.9% vs 5.1%vs APRNCT049084753 other results
| 22.4% vs 2.3%+20.1 vs placeboNCT042113639 other results
|
| PASI 100 | —Not posted · NCT03168256 | —Not posted · NCT06648772 |
| sPGA 0/1 | 21.6% vs 4.1%+17.5 vs placeboNCT0372117212 other results
| —Not posted · NCT06648772 |
| DLQI, change | -6.6 vs -2.1−4.5 vs placeboNCT0119421911 other results
| -2.6 vs -1.4−1.2 vs placeboNCT036382587 other results
|
PASI 75
- apremilast
- 33.1% vs 5.3%+27.8 vs placeboNCT01194219
10 other results
- 28.8% vs 5.8% NCT01232283
- 39.8% vs 11.9% NCT01690299
- 45.4% vs 16.1% NCT03701763
- 28.2% vs 7.1% NCT01988103
- 40.9% vs 5.7% NCT00773734
- 23.5% vs 7.1% NCT01988103
- 28.7% vs 5.7% NCT00773734
- 11.2% vs 5.7% NCT00773734
- 21.6% vs 8.2% NCT02425826
- 84.7% vs 18.8% NCT04908475
- Roflumilast (Zoryve)
- 41.6% vs 7.6%+34 vs placeboNCT04211363
9 other results
- 39% vs 5.3% NCT04211389
- 34.1% vs 16% NCT03638258
- 31.1% vs 16% NCT03638258
- 31.3% vs 13.2% NCT03638258
- 23% vs 13.2% NCT03638258
- 24.1% vs 9.6% NCT03638258
- 22.2% vs 9.6% NCT03638258
- 13.3% vs 10.5% NCT03638258
- 7.6% vs 10.5% NCT03638258
PASI 90
- apremilast
- 55.9% vs 5.1%vs APRNCT04908475
3 other results
- 11.4% vs 1.1% NCT00773734
- 9.2% vs 1.1% NCT00773734
- 4.5% vs 1.1% NCT00773734
- Roflumilast (Zoryve)
- 22.4% vs 2.3%+20.1 vs placeboNCT04211363
9 other results
- 15.5% vs 2% NCT04211389
- 20.6% vs 7.8% NCT03638258
- 13.7% vs 7.8% NCT03638258
- 16.9% vs 6% NCT03638258
- 7.4% vs 6% NCT03638258
- 14.3% vs 3.2% NCT03638258
- 2.3% vs 3.2% NCT03638258
- 6% vs 2.3% NCT03638258
- 1.3% vs 2.3% NCT03638258
PASI 100
- apremilast
- —Not posted · NCT03168256
- Roflumilast (Zoryve)
- —Not posted · NCT06648772
sPGA 0/1
- apremilast
- 21.6% vs 4.1%+17.5 vs placeboNCT03721172
12 other results
- 33.1% vs 11.5% NCT03701763
- 21.7% vs 3.9% NCT01194219
- 22.2% vs 6.9% NCT03777436
- 20.4% vs 4.4% NCT01232283
- 21.7% vs 3.6% NCT01690299
- 75.4% vs 18.4% NCT04908475
- 29.6% vs 8.8% NCT01988103
- 33.7% vs 12.6% NCT00773734
- 23.9% vs 8.8% NCT01988103
- 25% vs 12.6% NCT00773734
- 10.5% vs 12.6% NCT00773734
- 30.4% vs 9.6% NCT02425826
- Roflumilast (Zoryve)
- —Not posted · NCT06648772
DLQI, change
- apremilast
- -6.6 vs -2.1−4.5 vs placeboNCT01194219
11 other results
- -5.3 vs -2.6 NCT03777436
- -5.2 vs -2.4 NCT03721172
- -6.7 vs -2.7 NCT01232283
- -8.4 vs -3.9 NCT01690299
- -8.7 vs -3.4 NCT03774875
- -2.2 vs 1.3 NCT01988103
- -4.4 vs -1.9 NCT00773734
- -0.5 vs 1.3 NCT01988103
- -5.9 vs -1.9 NCT00773734
- -3.2 vs -1.9 NCT00773734
- -4.8 vs -2.4 NCT02425826
- Roflumilast (Zoryve)
- -2.6 vs -1.4−1.2 vs placeboNCT03638258
7 other results
- -4.2 vs -1.4 NCT03638258
- -2.6 vs -1.6 NCT03638258
- -3.5 vs -1.6 NCT03638258
- -2.6 vs -1.8 NCT03638258
- -3.1 vs -1.8 NCT03638258
- -2.2 vs -1.9 NCT03638258
- -2.3 vs -1.9 NCT03638258
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. apremilast: 7 of 7 rows · Roflumilast (Zoryve): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | apremilast Rows use multiple source trials | Roflumilast (Zoryve) Rows use multiple source trials |
|---|---|---|
| BSA absolute change · percentage points Induction | -47.77% (n=559) vs -6.99% (n=278) placebo @ 16wk30 mg BIDa,b,c,d NCT01194219 · Phase 3 · monotherapy 11 other source trials-48.4% (n=269) vs -6.25% (n=136) placebo @ 16wk NCT01232283 · Phase 3 -4.12% (n=120) vs -0.79% (n=111) placebo @ 16wk30 mg NCT03777436 · Phase 3 -55.44% (n=163) vs -20.56% (n=82) placebo @ 16wk NCT03701763 · Phase 3 -3.45% (n=261) vs -0.07% (n=249) placebo @ 16wk30 mg NCT03721172 · Phase 3 -19.8% (n=185) vs 18.5% (n=92) placebo @ 16wk30 mg NCT03774875 · Phase 4 · registry result, not featured evidence -47.7% (n=83) vs -16.3% (n=84) placebo @ 16wk NCT01690299 · Phase 3 · registry result, not featured evidence -21.6% (n=85) vs 7.5% (n=84) placebo @ 16wk20 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence -30.5% (n=85) vs 7.5% (n=84) placebo @ 16wk30 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence -28.3% (n=87) vs -8% (n=88) placebo @ 16wk10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence -38% (n=82) vs -8% (n=88) placebo @ 16wk20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence -50.4% (n=87) vs -8% (n=88) placebo @ 16wk30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence | -47.5% (n=113) vs -6.74% (n=109) placebo @ 12wk0.15%e,a,b,c,d NCT03638258 · Phase 2 · registry result, not featured evidence show 1 more dose-48.56% (n=109) vs -6.74% (n=109) placebo @ 12wk0.3% NCT03638258 · Phase 2 · registry result, not featured evidence |
| PASI absolute change · score Induction | -3.47 vs -0.54 placebo score @ 16wk30 mga,b,c,d NCT03721172 · Phase 3 | -68.03 vs -13.65 placebo score @ 12wk0.15%e,a,b,c,d NCT03638258 · Phase 2 · registry result, not featured evidence show 1 more dose-59.48 vs -13.65 placebo score @ 12wk0.3% NCT03638258 · Phase 2 · registry result, not featured evidence |
| PASI 75 responder rate · % of participants No placebo or comparator arm | 39.8% (n=88) @ 24wk30 mg BIDe,b,c NCT00773734 · Phase 2 · registry result, not featured evidence show 2 more doses26.4% (n=87) @ 24wk20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 18% (n=89) @ 24wk10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence | 49.6% (n=230) @ 24wk*e,b,c NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 114 Participants as posted show 1 more dose55.9% (n=102) @ 24wk* NCT03764475 · Phase 2 · registry result, not featured evidence · converted to % from 57 Participants as posted |
| Dropout rate | —30 mg BIDf NCT01194219 · Phase 3 show 67 more results10.5%30 mg BID NCT01194219 · Phase 3 · monotherapy —30 mg BID NCT01194219 · Phase 3 —30 mg BID NCT01194219 · Phase 3 13.1%Apremilast NCT01232283 · Phase 3 —Apremilast: Weeks 0-16 (PBO-Contro NCT01232283 · Phase 3 —Apremilast: Weeks 0-260 (APR- Expo NCT01232283 · Phase 3 —30 mg NCT03123471 · Phase 3 16.4%Apremilast NCT03123471 · Phase 3 —Apremilast /Apremilast (APR Exposu NCT03123471 · Phase 3 —Apremilast Total (APR Exposure Per NCT03123471 · Phase 3 —30 mg NCT03777436 · Phase 3 16.8%30 mg NCT03777436 · Phase 3 —30 mg BID NCT03701763 · Phase 3 —30 mg BID NCT03701763 · Phase 3 —20 mg BID NCT03701763 · Phase 3 —20 mg BID NCT03701763 · Phase 3 8.6%Apremilast NCT03701763 · Phase 3 —BID NCT03701763 · Phase 3 —BID NCT03701763 · Phase 3 13.1%30 mg NCT03721172 · Phase 3 —Apremalist: Placebo-controlled Pha NCT03721172 · Phase 3 —Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 50% NCT03022617 · Phase 4 · registry result, not featured evidence 17.8%30 mg NCT03774875 · Phase 4 · registry result, not featured evidence —30 mg NCT03774875 · Phase 4 · registry result, not featured evidence —30 mg NCT03774875 · Phase 4 · registry result, not featured evidence 44.3% NCT03082729 · Phase 4 · registry result, not featured evidence 54% NCT03587194 · Phase 4 · registry result, not featured evidence · combination 5% NCT03000309 · Phase 4 · registry result, not featured evidence 18.2%Apremilast NCT02425826 · Phase 4 · registry result, not featured evidence —Placebo-Controlled Phase: Apremila NCT02425826 · Phase 4 · registry result, not featured evidence 22% NCT02400749 · Phase 4 · registry result, not featured evidence 71.4%30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence · combination 50%30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence —30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence —30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence —30 mg NCT03930186 · Phase 3 · registry result, not featured evidence 7.9%Apremilast NCT03930186 · Phase 3 · registry result, not featured evidence —30 mg NCT01690299 · Phase 3 · registry result, not featured evidence 7.2%Apremilast Plus Placebo Injection NCT01690299 · Phase 3 · registry result, not featured evidence —Apremilast Plus Placebo Injection NCT01690299 · Phase 3 · registry result, not featured evidence —Apremilast/Apremilast NCT01690299 · Phase 3 · registry result, not featured evidence 17.9% NCT03442088 · Phase 2 · registry result, not featured evidence 12.5%30 mg NCT02576678 · Phase 2 · registry result, not featured evidence 38.5%20 mg NCT02576678 · Phase 2 · registry result, not featured evidence 23.8%20 mg NCT02576678 · Phase 2 · registry result, not featured evidence —30 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence —30 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence —20 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence —20 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence 20.5%30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 24.1%20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 11.2%10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —20 mg NCT00521339 · Phase 2 · registry result, not featured evidence 38.7%20 mg NCT00521339 · Phase 2 · registry result, not featured evidence —20 mg/20 mg NCT00521339 · Phase 2 · registry result, not featured evidence —20 mg/30 mg NCT00521339 · Phase 2 · registry result, not featured evidence | 10.8%0.3% creamf NCT04211363 · Phase 3 show 10 more results9%0.3% cream NCT04211389 · Phase 3 0%0.3% daily NCT04746911 · Phase 2 · registry result, not featured evidence 0%0.3% cream NCT04655313 · Phase 2 · registry result, not featured evidence 28.7%Cohort 1: Study 201 Participants NCT03764475 · Phase 2 · registry result, not featured evidence 21.6%Cohort 2: Non-study 201 Participan NCT03764475 · Phase 2 · registry result, not featured evidence 8%0.15% NCT03638258 · Phase 2 · registry result, not featured evidence —0.3% NCT03638258 · Phase 2 · registry result, not featured evidence 0%0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.15% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —30 mg BIDf NCT01194219 · Phase 3 show 67 more results4.1%30 mg BID NCT01194219 · Phase 3 · monotherapy —30 mg BID NCT01194219 · Phase 3 —30 mg BID NCT01194219 · Phase 3 4.4%Apremilast NCT01232283 · Phase 3 —Apremilast: Weeks 0-16 (PBO-Contro NCT01232283 · Phase 3 —Apremilast: Weeks 0-260 (APR- Expo NCT01232283 · Phase 3 —30 mg NCT03123471 · Phase 3 4%Apremilast NCT03123471 · Phase 3 —Apremilast /Apremilast (APR Exposu NCT03123471 · Phase 3 —Apremilast Total (APR Exposure Per NCT03123471 · Phase 3 —30 mg NCT03777436 · Phase 3 7%30 mg NCT03777436 · Phase 3 —30 mg BID NCT03701763 · Phase 3 —30 mg BID NCT03701763 · Phase 3 —20 mg BID NCT03701763 · Phase 3 —20 mg BID NCT03701763 · Phase 3 3.1%Apremilast NCT03701763 · Phase 3 —BID NCT03701763 · Phase 3 —BID NCT03701763 · Phase 3 2.4%30 mg NCT03721172 · Phase 3 —Apremalist: Placebo-controlled Pha NCT03721172 · Phase 3 —Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence — NCT03022617 · Phase 4 · registry result, not featured evidence 8.6%30 mg NCT03774875 · Phase 4 · registry result, not featured evidence —30 mg NCT03774875 · Phase 4 · registry result, not featured evidence —30 mg NCT03774875 · Phase 4 · registry result, not featured evidence 5.7% NCT03082729 · Phase 4 · registry result, not featured evidence — NCT03587194 · Phase 4 · registry result, not featured evidence · combination — NCT03000309 · Phase 4 · registry result, not featured evidence 3.4%Apremilast NCT02425826 · Phase 4 · registry result, not featured evidence —Placebo-Controlled Phase: Apremila NCT02425826 · Phase 4 · registry result, not featured evidence 6% NCT02400749 · Phase 4 · registry result, not featured evidence —30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence · combination —30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence —30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence —30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence —30 mg NCT03930186 · Phase 3 · registry result, not featured evidence 3.9%Apremilast NCT03930186 · Phase 3 · registry result, not featured evidence —30 mg NCT01690299 · Phase 3 · registry result, not featured evidence 2.4%Apremilast Plus Placebo Injection NCT01690299 · Phase 3 · registry result, not featured evidence —Apremilast Plus Placebo Injection NCT01690299 · Phase 3 · registry result, not featured evidence —Apremilast/Apremilast NCT01690299 · Phase 3 · registry result, not featured evidence 3.6% NCT03442088 · Phase 2 · registry result, not featured evidence 0%30 mg NCT02576678 · Phase 2 · registry result, not featured evidence 0%20 mg NCT02576678 · Phase 2 · registry result, not featured evidence 9.5%20 mg NCT02576678 · Phase 2 · registry result, not featured evidence —30 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence —30 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence —20 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence —20 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence 11.4%30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 9.2%20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 1.1%10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —20 mg NCT00521339 · Phase 2 · registry result, not featured evidence 6.5%20 mg NCT00521339 · Phase 2 · registry result, not featured evidence —20 mg/20 mg NCT00521339 · Phase 2 · registry result, not featured evidence —20 mg/30 mg NCT00521339 · Phase 2 · registry result, not featured evidence | 1.7%0.3% creamf NCT04211363 · Phase 3 show 10 more results0.3%0.3% cream NCT04211389 · Phase 3 —0.3% daily NCT04746911 · Phase 2 · registry result, not featured evidence —0.3% cream NCT04655313 · Phase 2 · registry result, not featured evidence 4.8%Cohort 1: Study 201 Participants NCT03764475 · Phase 2 · registry result, not featured evidence 2%Cohort 2: Non-study 201 Participan NCT03764475 · Phase 2 · registry result, not featured evidence 0%0.15% NCT03638258 · Phase 2 · registry result, not featured evidence —0.3% NCT03638258 · Phase 2 · registry result, not featured evidence —0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.15% NCT03392168 · Phase 1/2 · registry result, not featured evidence —0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | —30 mg BIDf NCT01194219 · Phase 3 show 67 more results—30 mg BID NCT01194219 · Phase 3 · monotherapy 9.2%30 mg BID NCT01194219 · Phase 3 2.1%30 mg BID NCT01194219 · Phase 3 —Apremilast NCT01232283 · Phase 3 1.8%Apremilast: Weeks 0-16 (PBO-Contro NCT01232283 · Phase 3 11.6%Apremilast: Weeks 0-260 (APR- Expo NCT01232283 · Phase 3 1%30 mg NCT03123471 · Phase 3 —Apremilast NCT03123471 · Phase 3 3%Apremilast /Apremilast (APR Exposu NCT03123471 · Phase 3 2.5%Apremilast Total (APR Exposure Per NCT03123471 · Phase 3 0.9%30 mg NCT03777436 · Phase 3 2.1%30 mg NCT03777436 · Phase 3 1.8%30 mg BID NCT03701763 · Phase 3 0%30 mg BID NCT03701763 · Phase 3 0%20 mg BID NCT03701763 · Phase 3 2.5%20 mg BID NCT03701763 · Phase 3 —Apremilast NCT03701763 · Phase 3 0.9%BID NCT03701763 · Phase 3 1.2%BID NCT03701763 · Phase 3 0.3%30 mg NCT03721172 · Phase 3 2.2%Apremalist: Placebo-controlled Pha NCT03721172 · Phase 3 0.8%Period A: RZB NCT04908475 · Phase 4 · registry result, not featured evidence 0%Period B: APR/APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 2.9%Period B: APR/RZB NCT04908475 · Phase 4 · registry result, not featured evidence —Period B: APR/RZB, NR NCT04908475 · Phase 4 · registry result, not featured evidence 6.9%Period B: RZB/RZB NCT04908475 · Phase 4 · registry result, not featured evidence 8.3% NCT03022617 · Phase 4 · registry result, not featured evidence —30 mg NCT03774875 · Phase 4 · registry result, not featured evidence 5.4%30 mg NCT03774875 · Phase 4 · registry result, not featured evidence 4.3%30 mg NCT03774875 · Phase 4 · registry result, not featured evidence 8.6% NCT03082729 · Phase 4 · registry result, not featured evidence 3.2% NCT03587194 · Phase 4 · registry result, not featured evidence · combination 0% NCT03000309 · Phase 4 · registry result, not featured evidence —Apremilast NCT02425826 · Phase 4 · registry result, not featured evidence 2%Placebo-Controlled Phase: Apremila NCT02425826 · Phase 4 · registry result, not featured evidence 6% NCT02400749 · Phase 4 · registry result, not featured evidence —30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence · combination —30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence 0%30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence 3.4%30 mg BID NCT02412644 · Phase 4 · registry result, not featured evidence 2.6%30 mg NCT03930186 · Phase 3 · registry result, not featured evidence —Apremilast NCT03930186 · Phase 3 · registry result, not featured evidence 7.2%30 mg NCT01690299 · Phase 3 · registry result, not featured evidence —Apremilast Plus Placebo Injection NCT01690299 · Phase 3 · registry result, not featured evidence 3.6%Apremilast Plus Placebo Injection NCT01690299 · Phase 3 · registry result, not featured evidence —Apremilast/Apremilast NCT01690299 · Phase 3 · registry result, not featured evidence 0% NCT03442088 · Phase 2 · registry result, not featured evidence 0%30 mg NCT02576678 · Phase 2 · registry result, not featured evidence 0%20 mg NCT02576678 · Phase 2 · registry result, not featured evidence 4.8%20 mg NCT02576678 · Phase 2 · registry result, not featured evidence 0%30 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence 1.7%30 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence 4.7%20 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence 9.1%20 mg BID NCT01988103 · Phase 2 · registry result, not featured evidence —30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 7.3%30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 4.5%30 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 7.4%20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 3.4%20 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence —10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 2.2%10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 0%10 mg BID NCT00773734 · Phase 2 · registry result, not featured evidence 0%20 mg NCT00521339 · Phase 2 · registry result, not featured evidence —20 mg NCT00521339 · Phase 2 · registry result, not featured evidence 0%20 mg/20 mg NCT00521339 · Phase 2 · registry result, not featured evidence 14.3%20 mg/30 mg NCT00521339 · Phase 2 · registry result, not featured evidence | 0.7%0.3% creamf NCT04211363 · Phase 3 show 10 more results0%0.3% cream NCT04211389 · Phase 3 0%0.3% daily NCT04746911 · Phase 2 · registry result, not featured evidence 0%0.3% cream NCT04655313 · Phase 2 · registry result, not featured evidence 3.5%Cohort 1: Study 201 Participants NCT03764475 · Phase 2 · registry result, not featured evidence 2%Cohort 2: Non-study 201 Participan NCT03764475 · Phase 2 · registry result, not featured evidence 0.9%0.15% NCT03638258 · Phase 2 · registry result, not featured evidence 0.9%0.3% NCT03638258 · Phase 2 · registry result, not featured evidence 0%0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence 0%0.15% NCT03392168 · Phase 1/2 · registry result, not featured evidence 0%0.5% NCT03392168 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | 30 mg BIDf upper respiratory tract infection 22.8% (placebo 2.6%) diarrhoea 20.3% (placebo 0%) nasopharyngitis 16.3% (placebo 3.9%) NCT01194219 · Phase 3 show 50 more results30 mg BID diarrhoea 18.8% (placebo 0%) nausea 15.7% (placebo 0%) upper respiratory tract infection 10.2% (placebo 2.6%) NCT01194219 · Phase 3 nausea 18.4% (placebo 3.2%) diarrhoea 15.8% (placebo 1.6%) nasopharyngitis 7.4% (placebo 8.1%) NCT01232283 · Phase 3 nasopharyngitis 18.2% (placebo 8.1%) nausea 17.9% (placebo 3.2%) diarrhoea 16.3% (placebo 1.6%) NCT01232283 · Phase 3 30 mg diarrhoea 30.5% (placebo 10.8%) nausea 21.5% (placebo 5.9%) headache 12% (placebo 4.9%) NCT03123471 · Phase 3 diarrhoea 31% (placebo 10.8%) nausea 23.5% (placebo 5.9%) headache 12.5% (placebo 4.9%) NCT03123471 · Phase 3 diarrhoea 26.8% (placebo 10.8%) nausea 19.4% (placebo 5.9%) headache 9.9% (placebo 4.9%) NCT03123471 · Phase 3 30 mg diarrhoea 11.8% (placebo 8.3%) nausea 7.4% (placebo 7.6%) headache 6.6% (placebo 11%) NCT03777436 · Phase 3 30 mg diarrhoea 25.9% (placebo 8.3%) headache 23.1% (placebo 11%) nausea 22.4% (placebo 7.6%) NCT03777436 · Phase 3 30 mg BID diarrhoea 11.7% (placebo 10%) psoriasis 9.9% (placebo 3.8%) nausea 9% (placebo 2.5%) NCT03701763 · Phase 3 30 mg BID diarrhoea 20.5% (placebo 10%) nausea 20.5% (placebo 2.5%) vomiting 15.7% (placebo 2.5%) NCT03701763 · Phase 3 20 mg BID diarrhoea 18.2% (placebo 10%) nausea 16.4% (placebo 2.5%) vomiting 13.6% (placebo 2.5%) NCT03701763 · Phase 3 20 mg BID abdominal pain 28.8% (placebo 10%) vomiting 20% (placebo 2.5%) diarrhoea 18.8% (placebo 10%) NCT03701763 · Phase 3 BID diarrhoea 14.9% (placebo 10%) nausea 12.7% (placebo 2.5%) vomiting 10% (placebo 2.5%) NCT03701763 · Phase 3 BID abdominal pain 19.6% (placebo 10%) diarrhoea 19.6% (placebo 10%) nausea 19.6% (placebo 2.5%) NCT03701763 · Phase 3 30 mg diarrhoea 16.4% (placebo 5.1%) headache 13.1% (placebo 5.1%) nausea 12.8% (placebo 4.4%) NCT03721172 · Phase 3 diarrhoea 14.3% (placebo 5.1%) headache 12.9% (placebo 5.1%) nausea 12.7% (placebo 4.4%) NCT03721172 · Phase 3 covid-19 11% nasopharyngitis 3.4% headache 2.5% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 12.5% nasopharyngitis 10.4% hypertension 6.3% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 11.8% nasopharyngitis 9.8% upper respiratory tract infection 5.9% NCT04908475 · Phase 4 · registry result, not featured evidence covid-19 16.4% nasopharyngitis 9.5% hypertension 5.2% NCT04908475 · Phase 4 · registry result, not featured evidence nausea 41.7% upper respiratory infection 25% acute gout 16.7% NCT03022617 · Phase 4 · registry result, not featured evidence 30 mg nasopharyngitis 11.3% (placebo 12%) diarrhoea 10% (placebo 6.5%) psoriasis 9% (placebo 10.9%) NCT03774875 · Phase 4 · registry result, not featured evidence 30 mg diarrhoea 33% (placebo 6.5%) headache 20% (placebo 5.4%) nausea 20% (placebo 5.4%) NCT03774875 · Phase 4 · registry result, not featured evidence nausea 20% diarrhea 15.7% headache 15.7% NCT03082729 · Phase 4 · registry result, not featured evidence diarrhea 16.1% nausea 12.9% folliculitis 6.5% NCT03587194 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.3% (placebo 16.4%) headache 20.4% (placebo 11%) nausea 17.7% (placebo 9.6%) NCT02425826 · Phase 4 · registry result, not featured evidence diarrhoea 18% (placebo 18%) headache 16% (placebo 14%) nausea 12% (placebo 12%) NCT02400749 · Phase 4 · registry result, not featured evidence 30 mg BID abdominal pain 25% (placebo 12.5%) worsening of psoriasis 12.5% (placebo 37.5%) bronchitis 0% (placebo 12.5%) NCT02412644 · Phase 4 · registry result, not featured evidence 30 mg BID first degree burn 37.9% (placebo 0%) bronchitis 3.4% (placebo 12.5%) worsening of psoriasis 3.4% (placebo 37.5%) NCT02412644 · Phase 4 · registry result, not featured evidence 30 mg diarrhoea 19.1% nausea 19.1% nasopharyngitis 18.4% NCT03930186 · Phase 3 · registry result, not featured evidence 30 mg diarrhoea 14.5% (placebo 3.6%) headache 14.5% (placebo 3.6%) nausea 14.5% (placebo 1.2%) NCT01690299 · Phase 3 · registry result, not featured evidence headache 13.3% (placebo 3.6%) diarrhoea 10.8% (placebo 3.6%) nausea 10.8% (placebo 1.2%) NCT01690299 · Phase 3 · registry result, not featured evidence arthroscopic procedure 3.6% contact dermatitis to watch 3.6% cough 3.6% NCT03442088 · Phase 2 · registry result, not featured evidence 30 mg diarrhoea 50% nausea 50% nasopharyngitis 37.5% NCT02576678 · Phase 2 · registry result, not featured evidence 20 mg nausea 61.5% headache 53.8% abdominal pain 46.2% NCT02576678 · Phase 2 · registry result, not featured evidence 20 mg abdominal pain 52.4% headache 52.4% nausea 47.6% NCT02576678 · Phase 2 · registry result, not featured evidence 30 mg BID nasopharyngitis 11.8% (placebo 8.3%) diarrhoea 9.4% (placebo 1.2%) abdominal discomfort 7.1% (placebo 1.2%) NCT01988103 · Phase 2 · registry result, not featured evidence 30 mg BID nasopharyngitis 29.2% (placebo 8.3%) diarrhoea 10% (placebo 1.2%) abdominal discomfort 6.7% (placebo 1.2%) NCT01988103 · Phase 2 · registry result, not featured evidence 20 mg BID nasopharyngitis 11.8% (placebo 8.3%) diarrhoea 8.2% (placebo 1.2%) abdominal discomfort 1.2% (placebo 1.2%) NCT01988103 · Phase 2 · registry result, not featured evidence 20 mg BID nasopharyngitis 23.1% (placebo 8.3%) diarrhoea 8.3% (placebo 1.2%) abdominal discomfort 2.5% (placebo 1.2%) NCT01988103 · Phase 2 · registry result, not featured evidence 30 mg BID nausea 22.6% (placebo 8%) upper respiratory tract infection 20.2% (placebo 4.5%) tension headache 14.5% (placebo 8%) NCT00773734 · Phase 2 · registry result, not featured evidence 30 mg BID nausea 19.3% (placebo 8%) tension headache 15.9% (placebo 8%) upper respiratory tract infection 15.9% (placebo 4.5%) NCT00773734 · Phase 2 · registry result, not featured evidence 20 mg BID nausea 16.5% (placebo 8%) upper respiratory tract infection 15.7% (placebo 4.5%) headache 10.7% (placebo 5.7%) NCT00773734 · Phase 2 · registry result, not featured evidence 20 mg BID nausea 14.9% (placebo 8%) upper respiratory tract infection 12.6% (placebo 4.5%) headache 9.2% (placebo 5.7%) NCT00773734 · Phase 2 · registry result, not featured evidence 10 mg BID upper respiratory tract infection 15.7% (placebo 4.5%) nausea 13.5% (placebo 8%) nasopharyngitis 11.2% (placebo 8%) NCT00773734 · Phase 2 · registry result, not featured evidence 10 mg BID nausea 11.2% (placebo 8%) upper respiratory tract infection 10.1% (placebo 4.5%) nasopharyngitis 9% (placebo 8%) NCT00773734 · Phase 2 · registry result, not featured evidence 20 mg diarrhoea 23.3% headache 20% nausea 20% NCT00521339 · Phase 2 · registry result, not featured evidence 20 mg/20 mg corneal abrasion 25% influenza like illness 25% joint dislocation 25% NCT00521339 · Phase 2 · registry result, not featured evidence 20 mg/30 mg epistaxis 28.6% pain in extremity 28.6% back pain 14.3% NCT00521339 · Phase 2 · registry result, not featured evidence | show 8 more results0.3% cream application site pain 5% back pain 5% candida infection 5% NCT04655313 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 6.5% NCT03764475 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 6.9% NCT03764475 · Phase 2 · registry result, not featured evidence 0.15% upper respiratory tract infection 6.4% (placebo 0%) NCT03638258 · Phase 2 · registry result, not featured evidence 0.3% upper respiratory tract infection 7.3% (placebo 0%) NCT03638258 · Phase 2 · registry result, not featured evidence 0.5% candiduria 12.5% (placebo 0%) application site erythema 0% (placebo 12.9%) application site pain 0% (placebo 16.1%) NCT03392168 · Phase 1/2 · registry result, not featured evidence 0.15% nasopharyngitis 7.1% (placebo 0%) application site erythema 3.6% (placebo 12.9%) application site pain 3.6% (placebo 16.1%) NCT03392168 · Phase 1/2 · registry result, not featured evidence 0.5% application site erythema 13.3% (placebo 12.9%) application site pain 6.7% (placebo 16.1%) nasopharyngitis 6.7% (placebo 0%) NCT03392168 · Phase 1/2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 16 weeks versus 12 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
apremilast
show 13 more results
show 8 more results
show 9 more results
show 5 more results
show 7 more results
show 4 more results
show 4 more results
show 20 more results
+ 75 further endpoints in the CSV export.
Roflumilast (Zoryve)
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 1 more result
show 15 more results
show 1 more result
show 7 more results
show 7 more results
+ 4 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: apremilast's landscape · Roflumilast (Zoryve)'s landscape